Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VAXIGRIP TETRA (Sanofi-Aventis Australia Pty Ltd)
Product name
VAXIGRIP TETRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
influenza virus haemagglutinin
Registration type
EOI
Indication
VAXIGRIP TETRA (suspension for injection) is now also indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for:
- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see Sections 4.2 Dose and method of administration, 4.4 Special warnings and precautions for use, 4.6 Fertility, pregnancy and lactation and 5.1 Pharmacodynamic properties - clinical trials).